ZDA
RYTM icon

Zweig-DiMenna Associates’s Rhythm Pharmaceuticals RYTM Stock Holding History

Zweig-DiMenna Associates’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-81,600
Closed -$8.73M – 93
2025
Q4 		$8.73M Buy
+81,600
New +$8.66M 0.54% 61

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Zweig-DiMenna Associates's RYTM Position: Q1 2026 in Review

Zweig-DiMenna Associates sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 81,600 shares — an estimated $8.73M sold.

Zweig-DiMenna Associates first reported a position in RYTM in Q4 2025 and held it in 1 quarter. The position peaked at $8.73M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Zweig-DiMenna Associates reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 81,600 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $8.73M.
  • Zweig-DiMenna Associates first reported a position in Rhythm Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Rhythm Pharmaceuticals position peaked at $8.73M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2026, filed 5 May 2026.